CYP17A1 is a cytochrome P450 monooxygenase that catalyzes critical steps in steroid hormone biosynthesis 1. The enzyme catalyzes 17-alpha hydroxylation of C21 steroids (pregnenolone and progesterone), followed by C17-C20 bond cleavage to generate C19 androgens (DHEA and androstenedione) 1. These 17-alpha hydroxy intermediates serve as precursors for cortisol synthesis in the glucocorticoid biosynthetic pathway. CYP17A1 mechanistically uses molecular oxygen, inserting one atom into substrates while reducing the second to water, with electrons supplied by NADPH via cytochrome P450 reductase. Spectroscopic studies demonstrate that the lyase reaction predominantly proceeds through a peroxo-driven catalytic pathway 1. Beyond canonical steroidogenesis, CYP17A1 regulates metabolic homeostasis; elevated hepatic expression increases 17-hydroxyprogesterone production, which activates glucocorticoid receptor signaling and promotes hyperglycemia and insulin resistance in obesity 2. CYP17A1 genetic variants associate with multiple disease phenotypes: the rs1004467 A allele increases hypertension risk 3, while rs74357 polymorphisms enhance polycystic ovary syndrome susceptibility 4. Clinically, CYP17A1 inhibitors represent therapeutic targets for hormone-dependent cancers including castration-resistant prostate cancer and breast cancer 5. The enzyme also exhibits 16-alpha hydroxylase activity relevant for estriol synthesis, expanding its role in reproductive endocrinology 6.